Eiger BioPharmaceuticals Inc. (EIGR)

11.42
NASDAQ : Health Technology
Prev Close 11.30
Day Low/High 11.33 / 11.50
52 Wk Low/High 8.40 / 15.33
Avg Volume 141.70K
Exchange NASDAQ
Shares Outstanding 24.43M
Market Cap 276.12M
EPS -3.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Eiger To Present At ChinaBio® Partnering Forum 2019

Eiger To Present At ChinaBio® Partnering Forum 2019

PALO ALTO, Calif., April 30, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals (EIGR) Shares Cross Below 200 DMA

Eiger BioPharmaceuticals (EIGR) Shares Cross Below 200 DMA

In trading on Thursday, shares of Eiger BioPharmaceuticals Inc crossed below their 200 day moving average of $12.00, changing hands as low as $10.94 per share. Eiger BioPharmaceuticals Inc shares are currently trading down about 14.8% on the day.

Eiger BioPharmaceuticals Becomes Oversold (EIGR)

Eiger BioPharmaceuticals Becomes Oversold (EIGR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Eiger BioPharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Eiger BioPharmaceuticals Announces Pricing Of Public Offering Of Common Stock

PALO ALTO, Calif., April 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock

Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock

PALO ALTO, Calif., April 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, And Biotech Veteran Amit K. Sachdev To Board Of Directors

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, And Biotech Veteran Amit K. Sachdev To Board Of Directors

PALO ALTO, Calif. , April 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals To Participate In Conferences In April

Eiger BioPharmaceuticals To Participate In Conferences In April

PALO ALTO, Calif., March 26, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals Management Team To Present And Participate In China Healthcare Investment Conference 2019

Eiger BioPharmaceuticals Management Team To Present And Participate In China Healthcare Investment Conference 2019

PALO ALTO, Calif., March 20, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update

Eiger BioPharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update

- Began 2019 with $100.4 million in cash, cash equivalents & short-term investments

Eiger Late-Breaker Oral Presentation Of Peginterferon Lambda Phase 2 LIMT Study At The International Liver Congress™ 2019

Eiger Late-Breaker Oral Presentation Of Peginterferon Lambda Phase 2 LIMT Study At The International Liver Congress™ 2019

- 36% Durable Virologic Response at 24 Weeks Post-Treatment

Eiger BioPharmaceuticals Management Team To Present And Participate In Jefferies HBV Investor Summit

Eiger BioPharmaceuticals Management Team To Present And Participate In Jefferies HBV Investor Summit

PALO ALTO, Calif., March 11, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.

Clinigen And Eiger BioPharmaceuticals Launch Worldwide Managed Access Program For Lonafarnib For Patients With Progeria And Progeroid Laminopathies

Clinigen And Eiger BioPharmaceuticals Launch Worldwide Managed Access Program For Lonafarnib For Patients With Progeria And Progeroid Laminopathies

Clinigen Group plc (AIM:CLIN, 'Clinigen'), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc.

EIGR Crosses Above Key Moving Average Level

EIGR Crosses Above Key Moving Average Level

In trading on Monday, shares of Eiger BioPharmaceuticals Inc crossed above their 200 day moving average of $11.28, changing hands as high as $12.07 per share. Eiger BioPharmaceuticals Inc shares are currently trading up about 8.7% on the day.

Eiger Announces Breakthrough Therapy Designation Granted By FDA For Lonafarnib In Progeria And Progeroid Laminopathies

Eiger Announces Breakthrough Therapy Designation Granted By FDA For Lonafarnib In Progeria And Progeroid Laminopathies

- Survival Benefit in Children with Progeria Published in JAMA 2018

Eiger BioPharmaceuticals Reports On 2018 R&D Day

Eiger BioPharmaceuticals Reports On 2018 R&D Day

-- Late Stage Rare and Ultra-Rare Disease Pipeline Advancing

Eiger BioPharmaceuticals To Host R&D Day In New York City

Eiger BioPharmaceuticals To Host R&D Day In New York City

PALO ALTO, Calif., Dec.

Eiger BioPharmaceuticals (EIGR) Shares Cross Above 200 DMA

Eiger BioPharmaceuticals (EIGR) Shares Cross Above 200 DMA

In trading on Monday, shares of Eiger BioPharmaceuticals Inc crossed above their 200 day moving average of $11.12, changing hands as high as $11.22 per share. Eiger BioPharmaceuticals Inc shares are currently trading up about 4.5% on the day.

Eiger BioPharmaceuticals Is Now Oversold (EIGR)

Eiger BioPharmaceuticals Is Now Oversold (EIGR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Eiger BioPharmaceuticals Becomes Oversold (EIGR)

Eiger BioPharmaceuticals Becomes Oversold (EIGR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.